{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-012556","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.524589+00:00","generated_at":"2026-06-20T11:54:54.858549+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TScan receives FDA clearance for three INDs in solid tumor program, including T-Plex and two MAGE-A1-targeting TCRs","bullets":["FDA cleared primary IND T-Plex enabling customized multiplexed TCR-T combinations based on tumor target/HLA expression.","Secondary INDs for TSC-204-A0201 and TSC-204-C0702 targeting MAGE-A1 on HLA A*02:01 and C*07:02 respectively.","MAGE-A1 overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.","TScan plans multicenter Phase 1 trial; screening protocol expected in Q2 2023, initial clinical data by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-012556","json":"https://secwatch.observer/filing/0001193125-23-012556.json","markdown":"https://secwatch.observer/filing/0001193125-23-012556.md","text":"https://secwatch.observer/filing/0001193125-23-012556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523012556/0001193125-23-012556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523012556/d449073d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:54:54.858549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}